Key Stats
Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.
Stock Score/grades
The Stock Score/Grades evaluate bankruptcy risk and assess the financial strength and fundamental health of a company
- Altman Z Score 7.14
- Piotroski Score 3.00
- Grade Buy
- Symbol (PRTA)
- Company Prothena Corporation plc
- Price $16.65
- Changes Percentage (-0.48%)
- Change -$0.08
- Day Low $16.07
- Day High $17.30
- Year High $55.89
Prothena Corporation plc, a late-stage clinical company, focuses on discovery and development of novel therapies for life-threatening diseases in the United States. The company is involved in developing Birtamimab, an investigational humanized antibody that is in Phase III clinical trial for the treatment of AL amyloidosis; Prasinezumab, a humanized monoclonal antibody, which is in Phase IIb clinical trial for the treatment of Parkinson's disease; PRX004 that completed Phase I clinical trial for the treatment of Transthyretin amyloidosis; and PRX005, which is in Phase I clinical trial for the treatment of Alzheimer's disease. Its discovery and preclinical programs include PRX012 for the treatment of Alzheimer's disease; and dual Aß-Tau vaccine for the treatment and prevention of Alzheimer's disease. Prothena Corporation plc has a license, development, and commercialization agreement with F. Hoffmann-La Roche Ltd. and Hoffmann-La Roche Inc. to develop and commercialize antibodies that target alpha-synuclein; and a collaboration agreement with Bristol-Myers Squibb to develop antibodies. The company was founded in 2012 and is based in Dublin, Ireland.
- Last Earnings
- Ex-Dividend for 5/16 Dividend
- Dividend Payable
- Today N/A
- Next Earnings (Estimated) 11/04/2024
- Fiscal Year End N/A
- Average Stock Price Target $56.00
- High Stock Price Target $98.00
- Low Stock Price Target $24.00
- Potential Upside/Downside N/A
- Consensus Rating Neutral
- Rating Score (0-4) N/A
- Research Coverage N/A
- EPS (Most Recent Fiscal Year) -$3.21
- Trailing P/E Ratio -6.58
- Forward P/E Ratio -6.58
- P/E Growth -6.58
- Net Income $-147,028,000
Income Statement
Quarterly
Annual
Latest News of PRTA
The Latest News section aggregates recent news posts from various news outlets, offering a comprehensive overview of the most recent developments related to the topic.
-
Prothena Corporation plc (PTRA): Positioning Among Top Debt-Free Stocks
Prothena Corporation plc (NASDAQ:PRTA) is among the best debt-free stocks to buy due to its focus on developing treatments for neurodegenerative diseases. With strong financials and strategic collabor...
By Yahoo! Finance | 1 month ago -
While shareholders of Prothena (NASDAQ:PRTA) are in the black over 5 years, those who bought a week ago aren't so fortunate
Prothena Corporation's stock price fell by 13% in a week, but long-term returns have been strong with a 146% gain over five years. Revenue growth has been impressive at 40% per year, indicating potent...
By Yahoo! Finance | 1 month ago -
Here's Why We're Not Too Worried About Prothena's (NASDAQ:PRTA) Cash Burn Situation
Despite the risk of cash burn, Prothena (NASDAQ:PRTA) seems to manage its finances well. With a 3.4-year cash runway, revenue growth, and potential breakeven in 4 years, shareholders need not worry....
By Yahoo! Finance | 3 months ago
